ALDX
NASDAQ
US
Aldeyra Therapeutics, Inc. - Common Stock
$1.66
▼ $-0.02
(-1.19%)
Vol 1.8M
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$99.9M
ROE
-63.7%
Beta
1.35
52W
$1–$6
Wall Street Consensus
12 analysts · Apr 20265
Strong Buy
5
Buy
2
Hold
0
Sell
0
Strong Sell
83.3%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 66.7%
Next Report
May 12, 2026
EPS Estimate: $-0.09
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.09 | $-0.10 | $-0.01 |
| Dec 2025 | $-0.17 | $-0.13 | +$0.04 |
| Sep 2025 | $-0.25 | $-0.16 | +$0.09 |
| Jun 2025 | $-0.25 | $-0.16 | +$0.09 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net Income | — | -$15.8M | -$9.9M | -$9.8M | -$7.7M | -$6.5M |
Fundamentals Trend
| Metric | 2025-12-03 | 2026-01-02 | 2026-04-02 | 2026-04-03 | 2026-04-04 | 2026-04-05 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -72.2% | -72.2% | -63.7% | -63.7% | -63.7% | -63.7% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 30.86 | 30.86 | — | — | — | — |
| Current Ratio | 2.72 | 2.72 | 2.58 | 2.58 | 2.58 | 2.58 |
Key Ratios
ROA (TTM)
-41.3%
P/B
7.0
EPS (TTM)
$-0.56
CF/Share
$-0.77
52W High
$6.18
52W Low
$1.07
$1.07
52-Week Range
$6.18
Financial Health
Free Cash Flow
-$5.3M
Net Debt
-$54.5M
Cash
$70.0M
Total Debt
$15.5M
As of Dec 31, 2025
How does ALDX compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
ALDX valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
7.0
▲
186%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
ALDX profitability vs Biotechnology peers
ROE
-63.8%
▲
5%
above
peers
(-67.3%)
vs Peers
vs Industry
In line
Net margin
—
▼
0%
below
peers
(-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-41.3%
▲
12%
above
peers
(-46.7%)
vs Peers
vs Industry
In line
ALDX financial health vs Biotechnology peers
D/E ratio
—
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
2.6
▼
42%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
1.4
▲
40%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
ALDX fundamentals radar
ALDX
Peer median
Industry
ALDX profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ALDX vs peers: key metrics
Post-Earnings Returns
| Quarter | Beat? | EPS Surprise | T+1 | T+5 |
|---|---|---|---|---|
| Mar 2026 | ✗ | $-0.01 | — | — |
Insider Activity
NeutralBuys
0
Sells
0
DOUGLAS RICHARD H
Director · Mar 19
70000 shs
ALFIERI MICHAEL L
Chief Financial Officer · Mar 18
5000 shs
Last 90 days
Top Holders
Top 5: 31.67%Knoll Capital Management, L…
9.10%
$9.7M
Perceptive Advisors Llc
6.95%
$7.4M
Blackrock Inc.
6.40%
$6.8M
Vanguard Group Inc
6.15%
$6.5M
Kingdon Capital Management …
3.07%
$3.3M
As of Dec 31, 2025
Latest News
No related news yet